Your browser doesn't support javascript.
loading
CXCR6 positions cytotoxic T cells to receive critical survival signals in the tumor microenvironment.
Di Pilato, Mauro; Kfuri-Rubens, Raphael; Pruessmann, Jasper N; Ozga, Aleksandra J; Messemaker, Marius; Cadilha, Bruno L; Sivakumar, Ramya; Cianciaruso, Chiara; Warner, Ross D; Marangoni, Francesco; Carrizosa, Esteban; Lesch, Stefanie; Billingsley, James; Perez-Ramos, Daniel; Zavala, Fidel; Rheinbay, Esther; Luster, Andrew D; Gerner, Michael Y; Kobold, Sebastian; Pittet, Mikael J; Mempel, Thorsten R.
Afiliação
  • Di Pilato M; Center for Immunology and Inflammatory Diseases, Massachusetts General Hospital, Boston, MA 02129, USA; Harvard Medical School, Boston, MA 02115, USA; Department of Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX 77054, USA. Electronic address: mdi@mdanderson.org.
  • Kfuri-Rubens R; Center for Immunology and Inflammatory Diseases, Massachusetts General Hospital, Boston, MA 02129, USA; Division of Clinical Pharmacology, Department of Medicine IV, Klinikum der Universität München, Munich, Germany.
  • Pruessmann JN; Center for Immunology and Inflammatory Diseases, Massachusetts General Hospital, Boston, MA 02129, USA; Harvard Medical School, Boston, MA 02115, USA.
  • Ozga AJ; Center for Immunology and Inflammatory Diseases, Massachusetts General Hospital, Boston, MA 02129, USA; Harvard Medical School, Boston, MA 02115, USA.
  • Messemaker M; Center for Systems Biology, Massachusetts General Hospital, Boston, MA 02115, USA.
  • Cadilha BL; Division of Clinical Pharmacology, Department of Medicine IV, Klinikum der Universität München, Munich, Germany.
  • Sivakumar R; Department of Immunology, University of Washington, Seattle, WA 98109, USA.
  • Cianciaruso C; Harvard Medical School, Boston, MA 02115, USA; Center for Systems Biology, Massachusetts General Hospital, Boston, MA 02115, USA.
  • Warner RD; Center for Immunology and Inflammatory Diseases, Massachusetts General Hospital, Boston, MA 02129, USA.
  • Marangoni F; Center for Immunology and Inflammatory Diseases, Massachusetts General Hospital, Boston, MA 02129, USA; Harvard Medical School, Boston, MA 02115, USA.
  • Carrizosa E; Center for Immunology and Inflammatory Diseases, Massachusetts General Hospital, Boston, MA 02129, USA; Harvard Medical School, Boston, MA 02115, USA.
  • Lesch S; Division of Clinical Pharmacology, Department of Medicine IV, Klinikum der Universität München, Munich, Germany.
  • Billingsley J; Harvard Chan Bioinformatics Core, Department of Biostatistics, Harvard School of Public Health, Boston, MA 21205, USA.
  • Perez-Ramos D; Department of Molecular Microbiology and Immunology and Malaria Research Institute, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD 21205, USA.
  • Zavala F; Department of Molecular Microbiology and Immunology and Malaria Research Institute, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD 21205, USA.
  • Rheinbay E; Center for Cancer Research, Massachusetts General Hospital, Boston, MA 02129, USA.
  • Luster AD; Center for Immunology and Inflammatory Diseases, Massachusetts General Hospital, Boston, MA 02129, USA; Harvard Medical School, Boston, MA 02115, USA.
  • Gerner MY; Department of Immunology, University of Washington, Seattle, WA 98109, USA.
  • Kobold S; Division of Clinical Pharmacology, Department of Medicine IV, Klinikum der Universität München, Munich, Germany; German Center for Translational Cancer Research (DKTK), partner site, Munich, Germany.
  • Pittet MJ; Harvard Medical School, Boston, MA 02115, USA; Center for Systems Biology, Massachusetts General Hospital, Boston, MA 02115, USA; Department of Pathology and Immunology, University of Geneva, Department of Oncology, Geneva University Hospitals, Geneva, Switzerland; Ludwig Institute for Cancer Resear
  • Mempel TR; Center for Immunology and Inflammatory Diseases, Massachusetts General Hospital, Boston, MA 02129, USA; Harvard Medical School, Boston, MA 02115, USA; Center for Systems Biology, Massachusetts General Hospital, Boston, MA 02115, USA. Electronic address: tmempel@mgh.harvard.edu.
Cell ; 184(17): 4512-4530.e22, 2021 08 19.
Article em En | MEDLINE | ID: mdl-34343496
ABSTRACT
Cytotoxic T lymphocyte (CTL) responses against tumors are maintained by stem-like memory cells that self-renew but also give rise to effector-like cells. The latter gradually lose their anti-tumor activity and acquire an epigenetically fixed, hypofunctional state, leading to tumor tolerance. Here, we show that the conversion of stem-like into effector-like CTLs involves a major chemotactic reprogramming that includes the upregulation of chemokine receptor CXCR6. This receptor positions effector-like CTLs in a discrete perivascular niche of the tumor stroma that is densely occupied by CCR7+ dendritic cells (DCs) expressing the CXCR6 ligand CXCL16. CCR7+ DCs also express and trans-present the survival cytokine interleukin-15 (IL-15). CXCR6 expression and IL-15 trans-presentation are critical for the survival and local expansion of effector-like CTLs in the tumor microenvironment to maximize their anti-tumor activity before progressing to irreversible dysfunction. These observations reveal a cellular and molecular checkpoint that determines the magnitude and outcome of anti-tumor immune responses.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Linfócitos T Citotóxicos / Microambiente Tumoral / Receptores CXCR6 Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Linfócitos T Citotóxicos / Microambiente Tumoral / Receptores CXCR6 Idioma: En Ano de publicação: 2021 Tipo de documento: Article